-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, A-share pharmaceutical companies have disclosed their 2021 transcrip.
47 companies have revenue of more than 10 billion yuan, 10 have a net profit of more than 4 billion yuan, and 18 have a gross profit margin of more than 9
In addition, the results for the first quarter of 2022 have also been releas.
Nine companies including Shanghai Pharmaceuticals and Jointown have a revenue of more than 10 billion yuan; 46 companies such as Renfu Pharmaceutical, Asymchem, and Proton have doubled their net profits, and 15 companies have exceeded 1 billi.
Yuan, Jiu'an Medical has become the "growth king" with a surge of more than 300 times, with a net profit of 13 billion yu.
Changchun High-tech, Zhifei Biological and others have entered the 1 billion echelon for the first time; 15 companies have a gross profit margin of over 90% and landed in January this ye.
Maiwei Bio on the Science and Technology Innovation Board won the "first brother" throne in one fell swo.
It is worth mentioning that there were 63 companies with net profit losses in the first quarter of this year, compared with only 35 companies in the same period in 202 Pharmaceutical stocks with net profit exceeding 14 billion appeared, 15 pharmaceutical companies with gross profit margin exceeding 90% and net profit exceeding 1 billion yuan in the first quarter of 2022 From the perspective of net profit, 46 companies have doubled their net profit, and 15 have a net profit exceeding 1 billion yu.
Jiu'an Medical increased from 304 million yuan to 13 billion yuan, a surge of more than 300 times, and became the "growth king" in the first quart.
Changchun High-tech, Zhifei Bio, Wantai Bio, Mingde Bio, and Aotai Bio entered the 1 billion echelon for the first ti.
In the same period last year, 11 net profit exceeded 1 billion yu.
In the first quarter of 2022, Jiu'an Medical's revenue was 274 billion yuan, a year-on-year increase of 6648%; net profit was 131 billion yuan, a year-on-year increase of 37527%; gross profit margin reached 86
The company's revenue in 2021 is 397 billion yuan, a year-on-year increase of 136%; net profit is 909 million yuan, a year-on-year increase of 2796%; gross profit margin is 64
For the skyrocketing performance, investors are most concerned about whether the performance can be sustain.
Jiu'an Medical stated at the 2021 and 2022 first quarter online performance briefings that the company's first quarter performance in 2022 increased significantly compared with the same period last year, mainly due to the increase in sales revenue of iHealth kit produc.
The demand for iHealth kit products is directly related to the development of the epidemic in the United States, and there is a strong uncertainty, which may greatly affect the demand for kit produc.
In addition, changes in the market competition environment will also have a certain impact on the sales of produc.
Therefore, it is currently impossible to accurately predict the future sales of the company's iHealth ki.
In the first quarter of 2022, there are 15 pharmaceutical companies with a gross profit margin exceeding 9
Among them, Maiwei Biotech, which landed on the Science and Technology Innovation Board in January this year, won the "first brother" throne in one fell swo.
Hualan Vaccines and Shenzhou cells ranked second and thi.
In addition, Tibet Pharmaceuticals entered the top ten, and no traditional Chinese medicine companies were shortlisted in the same period last ye.
Tibet Pharmaceutical's revenue in the first quarter of 2022 was 656 million yuan, a year-on-year increase of 374%; net profit was 175 million yuan, a year-on-year increase of 113%; gross profit margin reached 94
Tibet Pharmaceutical said that the company's star product, Xinhuosu, will continue to increase its volume in 2022, driving overall performance grow.
In the first quarter of 2022, pharmaceutical companies with operating income exceeding 10 billion yuan in terms of revenue, Shanghai Pharmaceuticals, Jiuzhoutong, Baiyunshan, e.
, all exceeded 10 billion yuan in sca.
Among them, Shanghai Pharmaceuticals thriving with 59 billion yuan, a year-on-year increase of more than 10 billion yu.
10%; Fosun Pharma and Jiu'an Medical broke the 10 billion mark for the first ti.
It is worth noting that due to the impact of the new crown epidemic in 2020, only 4 companies with revenue exceeding 10 billion yuan in the first quarter; 63 losses are amazing! This performance "flash crash", the net profit from 1 billion to a loss of 50 million According to the disclosed performance, 63 pharmaceutical companies lost money, of which 12 lost more than 100 million yu.
It is worth mentioning that, with the outbreak of the new crown epidemic in 2020, the demand for anti-epidemic and anti-epidemic products in the market has surged, and the performance of many related companies has ushered in explosive grow.
With the normalization of epidemic prevention and control, the demand for products has also begun to decrease, and the growth rate of some companies has declin.
Recently, Blue Sail Medical disclosed the report for the first quarter of 2022, revenue was 298 billion yuan, down 501% year-on-year; net profit loss was 545 million yuan, down 1005% year-on-year; gross profit margin was 15
In fact, Blue Sail Medical's performance decline has been traced in the annual repo.
The company's net profit in the first quarter of 2021 exceeded 7 billion yuan, exceeded 3 billion yuan in the first half of the year, and fell back to 156 billion yuan for the whole year, down 328% year-on-ye.
Blue Sail Medical said that the sharp decline in the company's performance was mainly affected by the protection divisi.
The disposable gloves industry in which the Protection Division is located is in a period of painful adjustment after explosive growth during the epidemic and the expansion of industry-wide production capaci.
The price of various glove products has dropped rapidly from the historical high during the epidemic, close to or even lower than the pre-epidemic lev.
Although the company has promoted a year-on-year increase of about 19% in the comprehensive sales of glove products through various measures, the increase in sales volume failed to make up for the decline in pric.
Over the same period, the price of raw materials fluctuated sharply and the cost of logistics and transportation increased, resulting in a sharp drop in the gross profit margin of glove produc.
In addition, although the global revenue of the cardiovascular and cerebrovascular business unit increased year-on-year, the R&D investment continued to increase, and the impact of non-cash expenses such as equity incentives was superimposed, resulting in an overall operating loss of about 773 million yuan for the business un.
The Nursing Division remained profitable and its net profit increased by nearly 10% year-on-ye.
With the gradual implementation of its capacity expansion, it is expected that there will still be a large room for growth in the futu.
On the other hand, the company's investment income lost 149 million yu.
In addition, although the performance of Inke Medical, known as the "Glove Mao", has not lost money, it has also experienced a sharp decli.
The company's revenue in the first quarter of 2022 was 288 billion yuan, down 603% year-on-year; net profit was 849 million yuan, down 977% year-on-ye.
In 2020 and 2021, the company's net profit will exceed 7 billion yuan, of which, in the first quarter of 2021, it will be as high as 7 billion yu.
Ingram Medical pointed out in its annual report that in the first quarter of 2021, the demand and price of gloves reached a peak level, and many glove companies around the world experienced a certain degree of capacity expansi.
With the gradual control of the epidemic situation in various countries, the demand for gloves has gradually normalized, and it will take some time to digest the inventory accumulated in different channe.
Due to the expansion of production capacity and the gradual return of demand to stability, the market is facing a situation of phased supply exceeding demand, and prices have continued to fa.
The sales prices of some channels have approached the pre-epidemic lev.
In addition, the current high cost of raw materials and energy and the re-imposition of.
tariffs present both opportunities and challenges in the indust.
The company will continuously and quickly adjust its business strategy in line with market chang.
Industry analysts pointed out that under the influence of the epidemic, the sales of some anti-epidemic and anti-epidemic products accelerated in the short term, bringing dividends to enterpris.
However, how to develop in the post-epidemic era is the biggest test for compani.
They should think more about innovation and transformation, not limited to developing existing businesses, expanding business scope and product lines, and seeking new performance growth poin.
The performance of A-share pharmaceutical companies in the first quarter of 2022 Source: Oriental Fortune Network, company announcements Note: If there are any omissions, please correct me!
47 companies have revenue of more than 10 billion yuan, 10 have a net profit of more than 4 billion yuan, and 18 have a gross profit margin of more than 9
In addition, the results for the first quarter of 2022 have also been releas.
Nine companies including Shanghai Pharmaceuticals and Jointown have a revenue of more than 10 billion yuan; 46 companies such as Renfu Pharmaceutical, Asymchem, and Proton have doubled their net profits, and 15 companies have exceeded 1 billi.
Yuan, Jiu'an Medical has become the "growth king" with a surge of more than 300 times, with a net profit of 13 billion yu.
Changchun High-tech, Zhifei Biological and others have entered the 1 billion echelon for the first time; 15 companies have a gross profit margin of over 90% and landed in January this ye.
Maiwei Bio on the Science and Technology Innovation Board won the "first brother" throne in one fell swo.
It is worth mentioning that there were 63 companies with net profit losses in the first quarter of this year, compared with only 35 companies in the same period in 202 Pharmaceutical stocks with net profit exceeding 14 billion appeared, 15 pharmaceutical companies with gross profit margin exceeding 90% and net profit exceeding 1 billion yuan in the first quarter of 2022 From the perspective of net profit, 46 companies have doubled their net profit, and 15 have a net profit exceeding 1 billion yu.
Jiu'an Medical increased from 304 million yuan to 13 billion yuan, a surge of more than 300 times, and became the "growth king" in the first quart.
Changchun High-tech, Zhifei Bio, Wantai Bio, Mingde Bio, and Aotai Bio entered the 1 billion echelon for the first ti.
In the same period last year, 11 net profit exceeded 1 billion yu.
In the first quarter of 2022, Jiu'an Medical's revenue was 274 billion yuan, a year-on-year increase of 6648%; net profit was 131 billion yuan, a year-on-year increase of 37527%; gross profit margin reached 86
The company's revenue in 2021 is 397 billion yuan, a year-on-year increase of 136%; net profit is 909 million yuan, a year-on-year increase of 2796%; gross profit margin is 64
For the skyrocketing performance, investors are most concerned about whether the performance can be sustain.
Jiu'an Medical stated at the 2021 and 2022 first quarter online performance briefings that the company's first quarter performance in 2022 increased significantly compared with the same period last year, mainly due to the increase in sales revenue of iHealth kit produc.
The demand for iHealth kit products is directly related to the development of the epidemic in the United States, and there is a strong uncertainty, which may greatly affect the demand for kit produc.
In addition, changes in the market competition environment will also have a certain impact on the sales of produc.
Therefore, it is currently impossible to accurately predict the future sales of the company's iHealth ki.
In the first quarter of 2022, there are 15 pharmaceutical companies with a gross profit margin exceeding 9
Among them, Maiwei Biotech, which landed on the Science and Technology Innovation Board in January this year, won the "first brother" throne in one fell swo.
Hualan Vaccines and Shenzhou cells ranked second and thi.
In addition, Tibet Pharmaceuticals entered the top ten, and no traditional Chinese medicine companies were shortlisted in the same period last ye.
Tibet Pharmaceutical's revenue in the first quarter of 2022 was 656 million yuan, a year-on-year increase of 374%; net profit was 175 million yuan, a year-on-year increase of 113%; gross profit margin reached 94
Tibet Pharmaceutical said that the company's star product, Xinhuosu, will continue to increase its volume in 2022, driving overall performance grow.
In the first quarter of 2022, pharmaceutical companies with operating income exceeding 10 billion yuan in terms of revenue, Shanghai Pharmaceuticals, Jiuzhoutong, Baiyunshan, e.
, all exceeded 10 billion yuan in sca.
Among them, Shanghai Pharmaceuticals thriving with 59 billion yuan, a year-on-year increase of more than 10 billion yu.
10%; Fosun Pharma and Jiu'an Medical broke the 10 billion mark for the first ti.
It is worth noting that due to the impact of the new crown epidemic in 2020, only 4 companies with revenue exceeding 10 billion yuan in the first quarter; 63 losses are amazing! This performance "flash crash", the net profit from 1 billion to a loss of 50 million According to the disclosed performance, 63 pharmaceutical companies lost money, of which 12 lost more than 100 million yu.
It is worth mentioning that, with the outbreak of the new crown epidemic in 2020, the demand for anti-epidemic and anti-epidemic products in the market has surged, and the performance of many related companies has ushered in explosive grow.
With the normalization of epidemic prevention and control, the demand for products has also begun to decrease, and the growth rate of some companies has declin.
Recently, Blue Sail Medical disclosed the report for the first quarter of 2022, revenue was 298 billion yuan, down 501% year-on-year; net profit loss was 545 million yuan, down 1005% year-on-year; gross profit margin was 15
In fact, Blue Sail Medical's performance decline has been traced in the annual repo.
The company's net profit in the first quarter of 2021 exceeded 7 billion yuan, exceeded 3 billion yuan in the first half of the year, and fell back to 156 billion yuan for the whole year, down 328% year-on-ye.
Blue Sail Medical said that the sharp decline in the company's performance was mainly affected by the protection divisi.
The disposable gloves industry in which the Protection Division is located is in a period of painful adjustment after explosive growth during the epidemic and the expansion of industry-wide production capaci.
The price of various glove products has dropped rapidly from the historical high during the epidemic, close to or even lower than the pre-epidemic lev.
Although the company has promoted a year-on-year increase of about 19% in the comprehensive sales of glove products through various measures, the increase in sales volume failed to make up for the decline in pric.
Over the same period, the price of raw materials fluctuated sharply and the cost of logistics and transportation increased, resulting in a sharp drop in the gross profit margin of glove produc.
In addition, although the global revenue of the cardiovascular and cerebrovascular business unit increased year-on-year, the R&D investment continued to increase, and the impact of non-cash expenses such as equity incentives was superimposed, resulting in an overall operating loss of about 773 million yuan for the business un.
The Nursing Division remained profitable and its net profit increased by nearly 10% year-on-ye.
With the gradual implementation of its capacity expansion, it is expected that there will still be a large room for growth in the futu.
On the other hand, the company's investment income lost 149 million yu.
In addition, although the performance of Inke Medical, known as the "Glove Mao", has not lost money, it has also experienced a sharp decli.
The company's revenue in the first quarter of 2022 was 288 billion yuan, down 603% year-on-year; net profit was 849 million yuan, down 977% year-on-ye.
In 2020 and 2021, the company's net profit will exceed 7 billion yuan, of which, in the first quarter of 2021, it will be as high as 7 billion yu.
Ingram Medical pointed out in its annual report that in the first quarter of 2021, the demand and price of gloves reached a peak level, and many glove companies around the world experienced a certain degree of capacity expansi.
With the gradual control of the epidemic situation in various countries, the demand for gloves has gradually normalized, and it will take some time to digest the inventory accumulated in different channe.
Due to the expansion of production capacity and the gradual return of demand to stability, the market is facing a situation of phased supply exceeding demand, and prices have continued to fa.
The sales prices of some channels have approached the pre-epidemic lev.
In addition, the current high cost of raw materials and energy and the re-imposition of.
tariffs present both opportunities and challenges in the indust.
The company will continuously and quickly adjust its business strategy in line with market chang.
Industry analysts pointed out that under the influence of the epidemic, the sales of some anti-epidemic and anti-epidemic products accelerated in the short term, bringing dividends to enterpris.
However, how to develop in the post-epidemic era is the biggest test for compani.
They should think more about innovation and transformation, not limited to developing existing businesses, expanding business scope and product lines, and seeking new performance growth poin.
The performance of A-share pharmaceutical companies in the first quarter of 2022 Source: Oriental Fortune Network, company announcements Note: If there are any omissions, please correct me!
